about us
CHF Solutions, Inc. is a privately held manufacturer
of innovative medical devices for cardiac care and the developer
of the aquapheresis therapy and the Aquadex FlexFlow Fluid Removal
system.
Fluid-overload is failure to eliminate excess fluid,
primarily salt and water, from the body. While many conditions such
as renal failure, metabolic disease and post-surgical conditions
may result in fluid-overload, congestive heart failure (CHF) is
a leading cause.
Aquapheresis therapy and the Aquadex FlexFlow Fluid
Removal system are designed specifically for use by physicians to
safely, effectively, and conveniently treat fluid-overloaded patients
by removing excess salt and water. With aquaphereis, the physician
specifies the amount of fluid to be removed from a patients blood
at a controlled rate and the system does so in a highly controlled
and effective way.
Mission Statement
The Company's mission is to provide medical practitioners
with innovative medical solutions that enable the treatment of patients
with unmet clinical needs. Through its products, the Company strives
to improve the quality of life, the medical outcomes, and the cost
savings for patients and hospitals alike.
Dr. Howard Levin, a cardiologist and biomedical
engineer, had long been frustrated by the lengthy time and inefficiencies
of existing fluid removal treatments. His vision was to develop
a simplified solution that would allow medical practitioners to
relieve fluid-overload more quickly, precisely and without the drawbacks
or side effects of traditional treatments. Dr. Levin partnered with
Mark Gelfand, an electrical engineer with 20 years of experience
in developing computer-controlled medical devices for life support.
Together, they founded CHF Solutions in July 1999.
Aquadex FlexFlow Fluid
Removal System
CHF Solutions' Aquadex FlexFlow is a technologically
sophisticated, yet easy-to-use mechanical pump/ultrafiltration system
that can remove up to 500mL/hr of excess fluid from the blood of
fluid-overloaded patients. It provides physicians with the ability
to precisely tailor the amount and rate of fluid removal per patient,
resulting in a gradual reduction of fluid with no clinically significant
effect on electrolyte balance or other hemodynamics.
Aquapheresis therapy can be used by the physician
in conjunction with, or as an alternative to diuretic or inotropic
drug therapies to achieve the target fluid removal goal for the
patient.
Whether its in an inpatient or outpatient clinical
setting, whether the patient has peripheral or central venous access,
the Aquadex FlexFlows low blood flow (10-40 mL/min), low extracorporeal
blood volume (33 mL), and precise removal rates (10 to 500mL/hr),
allows physicians and nurses to remove the salt and water they need
to, where and when they want to with no clinically significant impact
on electrolytes, heart rate, or blood pressure.
CHF Solutions aquapheresis therapy is comprised of
the Aquadex FlexFLow console, UF 500 filter circuit, and venous access
catheters. |
